GlaxoSmithKline (LSE: GSK) (NYSE: GSK) and Myogen, Inc. (Nasdaq: MYOG) today announced a two-part collaboration in Pulmonary Arterial Hypertension (PAH). Myogen licensed commercialization rights for ambrisentan, Myogen’s selective endothelin receptor antagonist (ERA) currently in Phase 3 development, to GlaxoSmithKline in all territories outside of the United States. Filing for marketing approval in the U.S. and Europe is expected later this year. Simultaneously, GlaxoSmithKline and Myogen entered into a distribution agreement whereby Myogen will be responsible for the marketing and distribution of GSK’s Flolan (epoprostenol sodium) a life-saving medicine for many patients, used in the treatment of PAH, in the United States.
